K-Ras(G12C) inhibitor 9 is primarily used in cancer research and treatment, specifically targeting cancers driven by the K-Ras(G12C) mutation. This mutation is commonly found in various cancers, including lung, colorectal, and pancreatic cancers. The inhibitor works by selectively binding to the mutated K-Ras protein, blocking its activity and preventing the signaling pathways that promote tumor growth and survival.

In clinical settings, it is being explored as a targeted therapy to improve outcomes for patients with K-Ras(G12C)-mutant cancers. Its application extends to preclinical studies, where it helps researchers understand the mechanisms of K-Ras-driven cancers and evaluate the efficacy of potential treatments. Additionally, it serves as a tool for developing combination therapies, where it may be used alongside other anticancer agents to enhance therapeutic effects.